The US pharmacovigilance market is expanding due to rising chronic diseases, stringent FDA regulations, and AI-driven ...

Many national reporting schemes have developed considerable experience and expertise over many years and have large ADR databases, which are national assets. Despite advances in pharmacovigilance ...

The respondents were encouraged to report ADRs if the reaction was serious (77, 77.8%) and unusual (70, 70.7%) in nature. Other factors that would influence ADR reporting include if the reaction ...